Author:
van Maldegem Febe,Downward Julian
Funder
Wellcome Trust
European Research Council
Cancer Research UK
Medical Research Council
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference10 articles.
1. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma;Ascierto;Nat. Med.,2019
2. Phase Ib study of combination therapy with MEK Inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS/RAF alterations;Bardia;Oncologist,2019
3. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity;Canon;Nature,2019
4. Kras and tumor immunity: friend or foe?;Cullis;Cold Spring Harb. Perspect. Med.,2018
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献